Background: Dexamethasone is commonly used to treat a wide variety of diseases including oncological disorders. The aim of this study was to propose a liquid formulation of dexamethasone. Therefore we have developed and assessed the stability of a 5 mg/mL dexamethasone oral suspension. Methods: A stability-indicating analytical method, using HPLC-UV, was developed and fully validated according to well-recognized international guidelines. The dexamethasone suspension was prepared using dexamethasone acetate powder and Ora-Sweet ® plus Ora-Plus
Introduction
Glucocorticoids are used in the treatment of a wide variety of oncological disorders including hematological malignancies such as leukemia, lymphoma and multiple myeloma [1] . For instance, among the drugs used for intensive multidrug chemotherapy to treat lymphoblastic leukemia and non-Hodgkin lymphoma, glucocorticoids are an essential component [2] . Indeed, owing to their ability to induce apoptosis in normal and neoplastic lymphoid cells, glucocorticoids are used to induce remission as well as during maintenance and continuing therapy of these malignant diseases [3] . Among the glucocorticoids available to treat these diseases, dexamethasone is the most commonly used since it has enhanced lymphoblast cytotoxicity [4] and improved central nervous system penetration leading to decreased risk of relapse [5] . For many patients (children, seniors, difficulty swallowing…), the use of a liquid formulation of dexamethasone is required [6] . However, current commercially liquid formulations of dexamethasone are unavailable in several countries. Moreover, commercial products [7] and extemporaneous compounds [8, 9] are unsuitable in many patients due to the presence of potentially harmful excipients (alcohol, propylene glycol, benzoic acid…) or to inappropriate dosage regarding the drug amount required for administration. Therefore, the aim of this study was to describe how to prepare a 5 mg/ml dexamethasone oral suspension and to perform a study in order to assess the stability of this dexamethasone oral suspension over 60 days. 
Materials and methods

Chemicals and reagents
Oral suspension compounding
Dexamethasone acetate powder was used to prepare an oral suspension at a level of 5 mg/mL using a 1:1 mixture of Ora-Sweet ® :Ora-Plus ® as liquid vehicles ( Figure 1 ).
The first step was to obtain a thick paste using 664.5 mg of dexamethasone acetate powder (corresponding to 600 mg of dexamethasone base) and 60 mL of wetting agent (Ora-Plus ® ). Then with constant stirring, the suspending agent was mixed 1:1 with 60 mL of the syrup vehicle (Ora-Sweet ® ) in order to obtain a final suspension containing dexamethasone base at a level of 5 mg/mL.
HPLC-UV analysis
Dexamethasone concentrations were determined using isocratic HPLC-UV. Separation Wavelength of the detector was set at 238nm. Chromatographic data were recorded and processed using EasyChrom ® software integrator. The system was operated at ambient temperature.
Method validation
A stability-indicating method, using high performance liquid chromatography coupled to u.v. spectrometry (HPLC-UV), has been developed, validated and performed to determine dexamethasone level. Validation of the analytical method was performed according to ICH Q2 R(1) international guidelines [10] carrying out the following criteria: linearity and accuracy (precision and trueness) of the method. 
Calibration curve
A calibration method was performed to assess dexamethasone concentration in the compounding vehicles. Initial 100 μg/mL dexamethasone solution was prepared dissolving 11.1 mg of dexamethasone acetate powder in 100 mL of methanol. This latter was then diluted in methanol to obtain a five-point calibration curve (0, 12.5, 25, 50, and 100 μg/mL). The calibration curve range was chosen according to the target concentration of dexamethasone in diluted oral suspension settled at 50 μg/ mL. The calibration line was generated by least-squares regression of the peak area versus dexamethasone concentrations profile.
Linearity and matrix effect
Linearity was assessed through calibration curves prepared on six different days and by analysis of correlation coefficient, y-intercept and slope of the linear regression line and the residuals (expressed as the percentage of the theoretical value).
Study of matrix effect was performed comparing the calibration curve prepared in methanol versus a calibration curve obtained using vehicles prepared as follows. Initial 5 mg/mL dexamethasone oral suspension was prepared as described above. This latter was then diluted in methanol (1:5, v:v) to obtain standard solution containing 1 mg/mL of dexamethasone and 10 % of oral suspension excipient. A five-point calibration curve was then performed, by doing geometric dilution of the standard solution to obtained working solution at 0, 12.5, 25, 50 and 100 μg/mL (corresponding at oral suspension levels of 0, 1.25, 2.5, 5, and 10 mg/mL). Dilution was performed with methanol containing 10 % of the corresponding oral suspension vehicle, allowing to maintain the same quantity of excipient in each calibration points. Samples were centrifuged at 3500 g for 10 min and supernatants were injected onto the column.
Y-intercept and slope of the linear regression lines were compared with a Student t test (α = 0.05) to assess the absence of a matrix effect.
Precision
To assess the precision (repeatability and intermediate precision) of the analytical method, quality controls were prepared at two concentration levels (12.5 and 50 μg/mL). Quality controls were prepared in methanol as described above. Precision was assessed through the determination of coefficient of variation of each quality control level, on the same day (n = 6) and over six days (n = 18) for repeatability and intermediate precision, respectively.
Trueness
Trueness was reported as percent recovery by the assay of the same quality controls (n = 18) used during precision study.
Specificity
To ensure that the method can suitably indicate the stability of the solution, we checked that the decomposition products obtained from the dexamethasone solution in methanol subjected to severe stress did not coelute with the intact drug [11] . The accelerated degradation study was performed heating to 100°C a methanolic solution of dexamethasone at a level of 100 μg/mL during 48h. After cooling at room temperature, samples were injected onto the column in order to compare chromatograms obtained to those obtained from the non-heated same solution.
Stability study
In order to assess physical and chemical stability of dexamethasone oral suspension, six batches of the formulation were prepared and stored at 4 ± 2°C or at 21 ± 3°C (temperature was daily monitored). The suspension was packaged in amber type I glass bottles (20 mL).
After storage in different appropriate conditions, suspensions were inspected visually and the pH was determined using an Ecoscan pH 6 ® pH/mV/°C Meter (Eutech Instruments, Singapore). Visual inspection was performed in transparent glass vial in order to check initial light pink colour and opalescent aspect of the suspension. Finally, dexamethasone content of oral suspension was determined using HPLC-UV, at day 0, 7, 14, 30 and 60. Oral suspension samples were diluted in methanol (1:10, v:v), centrifuged at 3500 g for 10 min and supernatants were then diluted in methanol (1:10, v:v) before injection onto the column. The mean percentage remaining were compared using a Student t test (α = 0.05) to assess the temperature impact.
Results
Method validation
Linearity and matrix effect and correlation coefficients (r²) of the linear regression line were equal to 0.99987 ( ± 0.0001), on average. Slope and y-intercept values provided by calibration curves prepared in methanol were not statistically significant from those provided by calibration curves obtained using vehicles (p = 0.612 and p = 0.175 for slope and y-intercept, respectively). These results are in accordance with the absence of matrix effect due to the suspending vehicles, therefore calibration curves may be performed using dexamethasone methanolic solution.
Accuracy
The analytical method was accurate as demonstrated by precision (repeatability and intermediate precision) and trueness studies. Indeed, coefficients of variation obtained during repeatability and intermediate precision studies were equal to or less than 0.42 % and 1.20 % respectively, whatever was the quality control level. The mean percent recoveries obtained during the trueness study remained equal to or higher than 96.61 %, whatever was the quality control level.
Specificity
Several degradation by-products were formed by forced decomposition of dexamethasone solution using heat stress (Figure 2 ). However none of them interfere with dexamethasone. Indeed, chromatograms obtained using stressed solution of dexamethasone provided excellent separation between dexamethasone and by-products peaks since they are fully resolved from one other ( Figure 2B ). Moreover, after complete degradation of dexamethasone, no by-product peak was observed at the retention time of dexamethasone ( Figure 2C) . Therefore, the developed method has been considered as a stability-indicating assay according to well-recognized requirements [11] .
Stability study
The HPLC-UV method developed has been used successfully for dexamethasone determination in oral suspensions (Figure 3 ). After preparation, the mean dexamethasone concentration of the compounded oral suspensions was equal to 5.07 ± 0.17 mg/mL.
Regarding physical stability of the compounded suspensions, no colour modifications, precipitate or suspending troubles was observed throughout the storage period. Moreover, less than 0.2 pH unit modifications of the oral suspensions were observed throughout the stability study (from 4.41 ± 0.01 to 4.20 ± 0.02).
Regarding chemical stability of the compounded suspensions, the mean dexamethasone concentrations determined by HPLC-UV analysis were equal to or higher than 4.88 ± 0.12 mg/mL, for the different days and storage conditions assessed (Figure 3) . Thereby, as shown in Table 1 , dexamethasone concentrations remained stable over the 60 days of the study, in both storage conditions (at 4 ± 2°C and at 21 ± 3°C). Moreover, no statistically significant differences were observed between the mean percentages remaining of dexamethasone in preparations stored at 4 ± 2°C versus 21 ± 3°C for the different days assessed (p > 0.105).
Discussion
Liquid formulations of dexamethasone are commercially available, at least in North America (Intensol ® Roxane Laboratories, USA; Dexamethasone elixir, Morton Grove Pharmaceuticals, USA). However, these latter contain potentially harmful excipients such as alcohol, propylene glycol, or benzoic acid, which makes them unsuitable for many patients such as neonates, children or patient suffering from oropharyngeal mycosis for instance. Moreover, these commercial products as well as the compounded formulations proposed by others contain low dexamethasone concentration ranging from 0.1 mg/mL to 1 mg/mL [8, 9] . Therefore, the strengths of these non-concentrated solutions are suitable to treat rheumatic and endocrine disorders as well as chemotherapy induced nausea and vomiting [12] . However, they require large-volume doses and are thereby inappropriate to treat diseases requiring high dosage regimen of dexamethasone such as haematological malignancies [13] .
In the light of all this, we have developed a 5 mg/mL dexamethasone oral suspension to be used as an alternative to the currently available commercial products and to extemporaneously compounded dexamethasone proposed by Ensom and Décarie. The dexamethasone content determined in the oral suspension compounded in this study highlights that the developed formulation allows a mean recovery of dexamethasone higher than 98 %. Thereby, these results demonstrate that almost no drug was lost during preparation and that the oral suspension compounded using the proposed vehicles provides reliable dosage of dexamethasone. Moreover, the oral formulation proposed in this study was compounded using dexamethasone acetate powder, which is the dexamethasone salt HPLC-UV chromatogram of a calibration standard (50 µg/mL) corresponding to a 5 mg/mL dexamethasone oral suspension (A), and HPLC-UV chromatograms of a dexamethasone oral suspension (5 mg/mL) assessed at day 0 (B) and at day 60 after storage at 21 ± 3°C (C).
used for oral medicines commercially available, while others have used dexamethasone sodium phosphate for injection to prepare their oral formulations [8] . However, it has been reported that dexamethasone sodium phosphate for injection is not bioequivalent to oral forms commercially available, when administered orally, requiring dosing adjustments [14] . Whatever storage condition was used, no significant degradation of dexamethasone occurred in compounded oral suspensions. Indeed, during the period of testing, the proportion of the initial dexamethasone concentration remaining was higher than 90 %, the limit set by the U.S. Pharmacopeia [15] , meaning that dexamethasone oral suspension was stable under regular storage temperatures (at 4 ± 2°C or at 21 ± 3°C). In temperature conditions exceeding 24°C, dexamethasone oral suspension should be storage in the fridge, between 2°C and 6°C.
These results are in accordance with data previously reported by others assessing the stability of compounded dexamethasone oral formulations [8, 9] .
The microbiological stability of Ora-Sweet ® and OraPlus ® has been already demonstrated, for hydrochlorothiazide and captopril suspensions for instance [16] . However, further investigations could be performed in order to assess microbiological stability of our dexamethasone suspension in "real life" conditions.
Conclusion
The formulation proposed in this study provides an appropriate and easy to use dosage form for oral dexamethasone administration. Moreover, according to the findings of this work, the dexamethasone oral suspension prepared under our conditions is physico-chemically stable up to 60 days at least, at 4 ± 2°C or at 21 ± 3°C. 
